Critical Analysis: GeoVax Labs (GOVX) & Its Peers

GeoVax Labs (NASDAQ:GOVX) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare GeoVax Labs to related businesses based on the strength of its valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Valuation & Earnings

This table compares GeoVax Labs and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
GeoVax Labs	$2.49 million	-$21.47 million	-0.18
GeoVax Labs Competitors	$756.09 million	$13.58 million	-19.00

GeoVax Labs’ competitors have higher revenue and earnings than GeoVax Labs. GeoVax Labs is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for GeoVax Labs and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1	1	1	0	2.00
GeoVax Labs Competitors	9869	15283	45612	1598	2.54

GeoVax Labs currently has a consensus target price of $3,600.00, indicating a potential upside of 179,451.12%. As a group, “Biotechnology” companies have a potential upside of 99.39%. Given GeoVax Labs’ higher possible upside, analysts clearly believe GeoVax Labs is more favorable than its competitors.

Insider and Institutional Ownership

6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 0.2% of GeoVax Labs shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares GeoVax Labs and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
GeoVax Labs Competitors	-12,323.33%	-195.38%	-30.39%

Risk & Volatility

GeoVax Labs has a beta of 3.85, indicating that its stock price is 285% more volatile than the S&P 500. Comparatively, GeoVax Labs’ competitors have a beta of -1.84, indicating that their average stock price is 284% less volatile than the S&P 500.

Summary

GeoVax Labs competitors beat GeoVax Labs on 9 of the 13 factors compared.

GeoVax Labs Company Profile

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s technology platform is based primarily on modified vaccinia Ankara (MVA) and virus-like particle (VLP) vaccine technologies, which are designed to generate broad and durable immune responses. GeoVax’s pipeline has included GEO-CM04S1, a multivalent COVID-19 vaccine candidate intended to address emerging coronavirus variants, as well as investigational vaccines for HIV, hemorrhagic fever viruses such as Ebola and Marburg, and other infectious diseases.